PFIZER INC PFE Cash Flow

Pfizer inc (PFE)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Apr'18	Dec'17	Oct'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09
Operating Activities
Net income before allocation to noncontrolling interests
15,823	16,302	16,245	12,684	11,507	11,188	23,860	22,596	21,795	21,355	9,847	8,343	7,328	7,246	6,296	7,080	7,653	6,986	8,391	8,926	9,211	9,168	10,506	10,432	21,645	22,072	25,819	26,434	15,560	14,598	9,725	10,260	9,618	10,049	11,498	8,620	8,487	8,288	6,157	8,167	7,948	8,643	0	0	0
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
5,683	6,010	6,267	6,328	6,362	6,384	6,317	6,269	6,281	6,269	6,244	6,074	5,887	5,757	5,632	5,508	5,322	5,157	5,064	5,118	5,341	5,537	5,695	5,890	6,092	6,410	7,028	7,163	7,208	7,655	8,006	8,565	9,143	9,026	8,474	8,488	8,452	8,399	8,267	7,007	5,800	4,757	0	0	0
Asset write-offs and impairments
2,843	2,953	3,534	3,535	3,546	3,398	396	578	606	634	793	727	1,502	1,613	1,401	2,060	1,254	1,119	981	384	405	531	651	686	769	1,145	1,342	1,189	1,162	1,299	1,290	1,383	1,666	1,198	1,303	3,226	3,609	3,486	0	0	0	-	-	-	-
TCJA impact
-192	-323	-505	-813	-659	-596	-11,070	-10,728	-10,728	-10,660	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition-related in-process research and development charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal
-	-	-	-	-	-	-	-	-	-	-342	-1,776	-1,749	-1,712	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain associated with the transfer of certain product rights to an equity-method investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	459	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred taxes from continuing operations
783	614	836	-1,865	-2,559	-2,205	-3,625	-3,230	-2,154	-2,410	876	-370	-458	-700	-1,190	153	-183	-20	-611	-716	-66	320	825	1,325	1,151	1,726	2,323	2,166	2,102	786	-327	-395	-40	236	1,525	1,004	1,149	2,109	-9,434	-8,711	-9,283	-9,590	0	0	0
Deferred taxes from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-23	1,399	1,373	1,427	1,412	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Share-based compensation expense
597	718	715	954	952	949	927	831	804	840	754	692	766	691	713	709	650	669	650	652	605	586	529	512	477	523	537	526	540	481	434	422	427	419	401	406	389	405	442	423	416	349	0	0	0
Benefit plan contributions in excess of expense/income
433	336	524	582	554	1,095	919	708	667	961	979	934	845	712	588	632	596	617	795	917	974	199	154	-321	-268	-296	-463	34	1	-135	-1,413	-1,540	-1,451	-1,769	-241	-1,160	-1,223	-677	0	0	0	-	-	-	-
Other adjustments, net
727	1,086	721	1,208	1,344	1,269	167	-334	-463	-399	185	141	-33	-487	-100	-212	-413	152	150	325	472	430	684	380	357	182	-26	117	221	130	7	106	-9	-18	-91	-151	230	-49	184	185	-163	-199	0	0	0
Other changes in assets and liabilities, net of acquisitions and divestitures:
Other changes in assets and liabilities, net of acquisitions and divestitures
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0
Net cash provided by operating activities
14,023	12,588	13,557	14,306	15,542	15,827	18,178	17,808	17,201	16,802	15,754	15,602	15,968	16,192	15,049	15,332	15,816	14,688	15,389	14,832	14,829	17,084	17,209	18,646	18,316	17,684	16,908	16,011	16,275	16,746	17,059	16,495	18,372	20,240	21,237	23,481	22,456	11,454	10,021	7,439	7,080	16,587	0	0	0
Investing Activities
Purchases of property, plant and equipment
2,179	2,176	2,189	2,171	2,116	2,042	2,057	1,960	1,984	1,956	1,945	1,927	1,880	1,823	1,745	1,602	1,459	1,397	1,140	1,126	1,146	1,199	1,262	1,265	1,296	1,206	1,283	1,290	1,275	1,327	1,431	1,600	1,664	1,660	1,609	1,443	1,458	1,513	1,388	1,361	1,257	1,205	0	0	0
Purchases of short-term investments
7,984	6,835	8,896	12,618	12,166	11,677	15,491	15,324	14,808	14,596	7,256	9,607	13,169	15,957	22,683	21,296	24,524	28,581	35,728	45,902	49,779	50,954	45,128	42,179	40,740	42,761	43,358	35,286	28,416	24,018	19,577	22,283	21,439	18,447	19,521	14,110	12,256	11,082	-16,799	-38	19,785	35,331	0	0	0
Proceeds from redemptions/sales of short-term investments
8,839	9,183	12,595	13,085	14,719	17,581	17,276	17,282	14,533	10,302	14,507	18,174	23,724	29,414	27,140	34,338	37,284	40,064	48,100	47,062	50,507	47,374	45,002	47,420	42,310	41,127	34,933	25,447	23,569	25,302	26,332	23,890	19,742	14,176	3,427	-706	-3,136	5,699	20,110	39,161	47,041	42,364	0	0	0
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less
-568	-6,925	-4,005	431	2,483	3,917	315	135	-2,787	-2,058	7,945	545	933	4,218	-6,696	-2,499	-1,018	-5,768	-4,542	-5,551	-7,673	-3,930	-2,845	2,477	-2,819	4,277	2,201	-2,057	4,760	-1,459	-1,709	-1,548	-5,514	-10,874	0	0	0	-	-	-	-	-	-	-	-
Purchases of long-term investments
139	201	428	850	1,276	1,797	2,514	2,944	3,402	3,537	5,766	6,548	7,443	8,011	7,735	7,246	7,700	9,542	8,042	10,813	12,060	10,718	11,528	11,114	10,582	11,020	11,197	14,061	12,207	11,145	9,668	3,744	3,872	4,620	5,100	5,840	5,202	4,128	3,509	3,103	4,304	6,888	0	0	0
Proceeds from redemptions/sales of long-term investments
340	232	4,186	5,025	5,712	6,244	3,350	3,402	3,311	3,579	6,756	10,379	10,970	11,268	9,309	6,065	6,134	6,929	6,043	6,489	6,628	6,145	6,249	7,308	7,565	7,555	7,576	7,880	6,132	4,990	3,503	879	1,561	2,147	2,916	3,153	4,498	4,737	5,502	6,176	6,742	6,504	0	0	0
Payments to Acquire Businesses, Net of Cash Acquired
-	-	-	-	-	-	-	-	-	1,000	1,689	14,752	18,843	18,368	17,823	20,403	15,898	16,466	16,322	874	873	195	0	0	0	-	-	-	-	1,050	876	895	895	3,282	0	0	0	-	-	-	-	-	-	-	-
Acquisitions of intangible assets
292	418	471	389	280	154	0	0	0	-	-	-	-	-	-	-	-	99	90	340	385	384	424	188	139	259	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other investing activities, net
-142	-205	-185	-329	-298	-288	-400	-354	-431	-671	-539	-509	-371	-80	-58	-37	-20	-344	-368	-392	-471	-347	-443	-429	-362	-312	-383	-412	-370	-185	-89	-372	-468	-501	-30	328	98	-118	-88	-273	-135	-100	0	0	0
Net cash provided by/(used in) investing activities
-11,566	-3,945	-1,876	1,980	2,408	4,525	530	423	159	-4,740	-3,068	-4,438	-7,378	-7,791	-6,928	-7,790	-5,217	-2,980	-2,270	438	1,036	-5,654	-3,998	-2,066	284	-10,544	-3,849	-3,493	-5,223	6,154	-141	321	1,569	1,843	-4,344	-8,439	-9,161	-492	786	4,368	-8,244	-31,272	0	0	0
Financing Activities
Proceeds from short-term borrowings
21,148	16,455	13,348	5,921	3,892	3,711	3,406	5,411	6,338	8,464	8,078	9,964	9,344	7,472	9,932	5,842	4,240	5,557	2,027	2,034	2,012	13	608	1,990	3,292	4,323	6,018	6,565	7,465	7,995	8,897	11,706	11,689	12,810	11,327	8,099	7,190	6,400	7,372	12,574	22,277	31,159	0	0	0
Principal payments on short-term borrowings
14,163	8,378	4,286	3,891	3,710	4,437	6,527	7,780	9,921	9,947	9,431	7,890	6,262	5,093	7,270	6,245	5,315	3,965	23	14	7	10	461	1,908	3,206	4,234	0	0	0	-	-	-	-	13,276	3,810	4,411	7,222	9,249	14,258	19,797	26,532	34,969	0	0	0
Net proceeds from short-term borrowings with original maturities of three months or less
3,726	2,551	1,960	-990	498	-1,617	-117	3,249	3,449	1,422	-1,531	-4,977	-6,894	-3,060	-153	4,418	3,578	2,717	2,824	1,332	-2,009	-1,841	-1,114	-1,468	1,021	3,475	1,977	2,570	5,246	-30	7,977	4,013	703	1,910	0	0	0	-	-	-	-	-	-	-	-
Proceeds from issuance of long-term debt
1,241	4,942	4,942	9,916	9,916	4,974	4,975	1	1	5,274	11,218	11,218	16,249	10,976	0	0	0	-	-	-	-	-	-	-	-	6,618	6,618	6,618	2,624	0	0	0	0	-	-	-	-	-	-	-	-	24,023	0	0	0
Principal payments on long-term debt
5,983	6,806	6,268	5,817	6,215	3,566	4,784	4,785	5,256	6,154	7,846	7,845	7,406	7,689	4,313	4,312	1,528	2,990	4,318	4,353	4,356	2,110	2,536	2,504	4,896	4,146	3,895	3,900	1,512	1,513	3,514	3,512	3,111	6,986	3,488	3,485	3,875	6	61	61	673	967	0	0	0
Purchases of common stock
0	8,865	13,895	15,000	15,000	12,198	7,168	6,063	6,063	5,000	5,000	5,000	5,000	5,000	5,000	5,160	5,160	6,160	7,359	8,480	9,803	5,000	8,448	10,921	12,861	16,290	15,037	13,118	11,195	8,228	8,045	8,320	9,229	9,000	0	0	0	-	-	-	-	-	-	-	-
Cash dividends paid
8,103	8,043	8,014	8,004	7,991	7,978	7,924	7,825	7,746	7,659	7,571	7,497	7,408	7,317	7,225	7,132	7,036	6,940	6,850	6,772	6,705	6,609	6,524	6,464	6,507	6,580	6,645	6,687	6,619	6,534	6,439	6,358	6,293	6,234	6,254	6,252	6,238	6,088	5,824	5,343	4,856	5,548	0	0	0
Proceeds from exercise of stock options
392	394	463	1,033	1,013	1,259	1,305	925	921	862	729	734	1,036	1,019	1,044	978	765	1,263	1,463	1,400	1,371	1,002	1,084	1,158	1,533	1,750	1,583	1,545	1,175	568	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other financing activities, net
-478	-736	-702	-298	-588	-588	-941	-1,214	-886	-611	-567	-578	-624	-536	-254	-231	-145	109	-8	-12	-26	-123	97	78	88	109	0	0	0	-	-	-	-	16	118	53	89	66	42	92	-86	-91	0	0	0
Net cash used in financing activities
-2,218	-8,485	-12,452	-17,131	-18,188	-20,441	-17,777	-18,082	-19,163	-13,350	-11,920	-11,871	-6,964	-9,228	-8,209	-6,810	-10,602	-10,409	-12,242	-14,866	-15,032	-10,187	-12,804	-15,548	-17,542	-14,975	-15,464	-13,124	-12,058	-15,999	-16,016	-16,760	-17,710	-20,607	-15,436	-13,924	-14,367	-11,174	-12,829	-12,134	1,635	14,481	0	0	0
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
-59	-32	-41	-129	-159	-116	-130	1	87	53	-69	-110	-121	-215	-917	-990	-999	-1,000	-215	-140	-132	-83	-21	-62	-88	-63	-49	11	-36	-2	-102	-121	-27	-29	73	101	43	-31	-36	-40	41	60	0	0	0
Net increase in cash and cash equivalents and restricted cash and cash equivalents
179	125	-812	-974	-398	-205	799	151	-1,715	-1,235	699	-816	1,504	-1,041	-1,005	-259	-1,002	298	661	264	701	1,160	386	970	970	-7,898	-2,454	-595	-1,042	6,899	800	-65	2,204	1,447	1,530	1,219	-1,029	-243	-2,058	-367	512	-144	0	0	0
Receipt of ICU Medical common stock
-	-	-	-	-	-	-	-	-	428	428	428	428	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Promissory note from ICU Medical
-	-	-	-	-	-	-	-	-	75	75	75	75	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,479	2,479	2,479	2,479	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012(b)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Transfer of certain product rights to an equity-method investment (Hisun Pfizer)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,233	1,233	1,233	1,233	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes
3,668	3,664	4,625	4,594	3,633	3,655	2,731	2,565	2,551	2,489	2,515	2,531	2,198	2,521	2,399	2,370	2,529	2,383	2,030	2,156	1,936	2,100	2,559	2,637	2,862	2,874	2,313	2,587	2,506	2,409	3,283	3,317	3,512	2,927	1,795	1,201	1,094	11,775	12,071	12,502	12,393	2,300	0	0	0
Interest paid
1,674	1,587	1,589	1,396	1,437	1,311	1,385	1,361	1,561	1,518	1,375	1,429	1,258	1,451	1,317	1,291	1,379	1,302	1,383	1,468	1,521	1,550	1,546	1,622	1,657	1,729	1,710	1,782	1,798	1,873	1,888	1,942	1,906	2,085	1,988	2,150	2,050	2,155	2,251	1,978	1,643	935	0	0	0
Interest rate hedges
-20	-42	-12	-39	-91	-38	-120	-44	-211	-199	-165	-258	-279	-338	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-